Development Level

Tbio 315 | 10,625
Tchem 44 | 1,890
Tclin 18 | 602
Tdark 15 | 7,003

IMPC Term

preweaning lethality, complete... 21 | 633
embryonic lethality prior to o... 6 | 148
hypoactivity 5 | 89
preweaning lethality, incomple... 5 | 260
abnormal behavior 4 | 226
decreased caudal vertebrae num... 4 | 49
embryonic lethality prior to t... 4 | 187
abnormal retina morphology 3 | 100
decreased body length 3 | 108
increased leukocyte cell numbe... 3 | 37
increased or absent threshold ... 3 | 128
abnormal body wall morphology 2 | 7
abnormal bone structure 2 | 131
abnormal skin morphology 2 | 23
decreased bone mineral content 2 | 157
decreased bone mineral density 2 | 126
decreased lean body mass 2 | 195
decreased lumbar vertebrae num... 2 | 62
decreased total body fat amoun... 2 | 186
improved glucose tolerance 2 | 56
increased circulating HDL chol... 2 | 63
increased circulating LDL chol... 2 | 15
increased circulating alkaline... 2 | 119
increased circulating calcium ... 2 | 32
increased circulating free fat... 2 | 17
increased erythrocyte cell num... 2 | 26
increased grip strength 2 | 83
increased sacral vertebrae num... 2 | 62
abnormal bone mineralization 1 | 55
abnormal coat appearance 1 | 25
abnormal coping response 1 | 12
abnormal embryo size 1 | 112
abnormal epididymis morphology 1 | 31
abnormal femur morphology 1 | 14
abnormal gait 1 | 51
abnormal head morphology 1 | 10
abnormal heart morphology 1 | 51
abnormal kidney morphology 1 | 30
abnormal posture 1 | 5
abnormal retinal inner nuclear... 1 | 5
abnormal snout morphology 1 | 18
abnormal startle reflex 1 | 14
abnormal vibrissa morphology 1 | 17
absent pinna reflex 1 | 21
absent startle reflex 1 | 15
brachydactyly 1 | 2
decreased CD103-positive CD11b... 1 | 2
decreased CD4-positive, CD25-p... 1 | 24
decreased NK T cell number 1 | 28
decreased T cell number 1 | 31
decreased blood urea nitrogen ... 1 | 31
decreased body weight 1 | 174
decreased circulating LDL chol... 1 | 37
decreased circulating chloride... 1 | 32
decreased circulating creatini... 1 | 31
decreased circulating fructosa... 1 | 31
decreased circulating glycerol... 1 | 19
decreased circulating insulin ... 1 | 75
decreased circulating iron lev... 1 | 25
decreased circulating serum al... 1 | 79
decreased circulating sodium l... 1 | 18
decreased fasted circulating g... 1 | 49
decreased grip strength 1 | 123
decreased leukocyte cell numbe... 1 | 54
decreased mature B cell number 1 | 25
decreased mean corpuscular hem... 1 | 34
decreased mean corpuscular vol... 1 | 50
decreased prepulse inhibition 1 | 52
decreased startle reflex 1 | 48
decreased total retina thickne... 1 | 20
decreased vertical activity 1 | 22
enlarged epididymis 1 | 27
enlarged heart 1 | 111
enlarged spleen 1 | 26
impaired glucose tolerance 1 | 52
increased CD4-positive, alpha ... 1 | 15
increased blood urea nitrogen ... 1 | 44
increased bone mineral density 1 | 52
increased circulating choleste... 1 | 53
increased circulating phosphat... 1 | 24
increased circulating potassiu... 1 | 31
increased effector memory CD4-... 1 | 15
increased exploration in new e... 1 | 56
increased fasted circulating g... 1 | 68
increased heart weight 1 | 37
increased mean corpuscular hem... 1 | 93
increased mean corpuscular vol... 1 | 91
increased total body fat amoun... 1 | 57
male infertility 1 | 62
prenatal lethality prior to he... 1 | 64
protruding tongue 1 | 1
short tibia 1 | 82
vertebral transformation 1 | 12

Disease

ovarian cancer 218 | 8,484
osteosarcoma 151 | 7,933
lung cancer 141 | 4,466
psoriasis 122 | 6,685
medulloblastoma, large-cell 115 | 6,234
glioblastoma 104 | 5,572
Multiple myeloma 99 | 1,327
Cancer 94 | 2,346
atypical teratoid / rhabdoid tumor 79 | 4,369
diabetes mellitus 78 | 1,663
intraductal papillary-mucinous neoplasm (IPMN) 77 | 3,289
malignant mesothelioma 64 | 3,162
oligodendroglioma 61 | 2,849
Breast cancer 58 | 3,094
Waldenstrons macroglobulinemia 58 | 765
primitive neuroectodermal tumor 53 | 3,031
pediatric high grade glioma 52 | 2,712
pilocytic astrocytoma 50 | 3,086
subependymal giant cell astrocytoma 49 | 2,287
invasive ductal carcinoma 47 | 2,950
non-small cell lung cancer 46 | 2,798
ependymoma 44 | 2,514
Pick disease 43 | 1,893
acute quadriplegic myopathy 43 | 1,157
astrocytoma 43 | 1,493
intraductal papillary-mucinous carcinoma (IPMC) 42 | 2,988
dermatomyositis 41 | 933
group 3 medulloblastoma 39 | 2,254
intraductal papillary-mucinous adenoma (IPMA) 39 | 2,956
lung adenocarcinoma 37 | 2,713
adult high grade glioma 36 | 2,148
sonic hedgehog group medulloblastoma 35 | 1,482
ulcerative colitis 35 | 2,087
astrocytic glioma 34 | 2,241
lung carcinoma 34 | 2,844
pancreatic cancer 33 | 2,300
Anemia 32 | 252
pancreatic ductal adenocarcinoma liver metastasis 32 | 1,795
medulloblastoma 31 | 1,524
Carcinoma 30 | 2,147
Kidney disease 30 | 396
interstitial cystitis 30 | 2,299
juvenile dermatomyositis 30 | 1,189
Acquired immunodeficiency syndrome 29 | 164
Hypersensitivity reaction type II disease 28 | 235
Multiple Sclerosis 28 | 498
breast carcinoma 27 | 1,614
group 4 medulloblastoma 27 | 1,875
Arthritis 26 | 248
Liver disease 26 | 219
acute myeloid leukemia 26 | 780
colon cancer 26 | 1,475
primary pancreatic ductal adenocarcinoma 25 | 1,271
tuberculosis 25 | 1,557
Ankylosing spondylitis 24 | 138
Hepatitis B 24 | 103
Primary immunodeficiency disease 24 | 52
Rheumatoid Arthritis 24 | 1,160
cystic fibrosis 24 | 1,665
Diamond-Blackfan anemia 23 | 28
HIV Infections 23 | 100
Hemochromatosis 22 | 55
Uveitis 22 | 103
primary Sjogren syndrome 22 | 789
Behcet's disease 21 | 74
Juvenile rheumatoid arthritis 21 | 104
Leprosy 21 | 77
Skin disease 21 | 65
pituitary cancer 20 | 1,972
posterior fossa group A ependymoma 19 | 1,511
cutaneous lupus erythematosus 18 | 1,056
adrenocortical carcinoma 16 | 1,427
ductal carcinoma in situ 16 | 1,745
inflammatory breast cancer 16 | 404
Stomach Neoplasms 15 | 282
posterior fossa group B ependymoma 15 | 1,530
tuberculosis and treatment for 6 months 15 | 686
Cockayne syndrome 14 | 54
Prostatic Neoplasms 14 | 471
non primary Sjogren syndrome sicca 14 | 840
Alzheimer's disease 13 | 644
Anemia, Diamond-Blackfan 13 | 15
Mammary Neoplasms 13 | 410
atypical teratoid/rhabdoid tumor 13 | 1,095
hepatocellular carcinoma 13 | 532
progressive supranuclear palsy 13 | 674
spina bifida 13 | 1,064
Atopic dermatitis 12 | 944
IGA Glomerulonephritis 12 | 454
gastric carcinoma 12 | 832
Duchenne muscular dystrophy 11 | 602
Intellectual disability 11 | 573
esophageal adenocarcinoma 11 | 737
glioblastoma multiforme 11 | 347
mucosa-associated lymphoid tissue lymphoma 11 | 480
Mammary Neoplasms, Experimental 10 | 150
Osteoporosis 10 | 257
Photosensitive trichothiodystrophy 10 | 24
nasopharyngeal carcinoma 10 | 1,056
Disease Progression 9 | 125

Tissue

Blood and immune system 374 | 17,995
Endocrine System 374 | 18,512
Female tissues 374 | 18,647
Liver and Pancreas 374 | 18,136
Male tissues 374 | 17,969
Nervous System 374 | 18,561
Cardiovascular System 373 | 17,958
Digestive Tract 373 | 18,473
Urinary Tract 372 | 18,444
Respiratory system 371 | 17,484
Skin and soft tissues 367 | 18,115

Target Family

Non-IDG 281 | 11,971
Enzyme 84 | 4,146
Kinase 17 | 634
Epigenetic 3 | 242
Transporter 3 | 473
GPCR 2 | 406
Transcription Factor 2 | 1,400

Reactome Pathway

Infectious disease 392 | 392
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
HLA class I histocompatibility antigen, A-3 alpha chain HLA-A Tbio Non-IDG -3.60614 4042.7 585
Syntaxin-1B STX1B Tbio Non-IDG -1.74488 52.6 27
Nucleoprotein TPR TPR Tbio Non-IDG -2.07876 130.9 158
ADP/ATP translocase 3 SLC25A6 Tbio Transporter -2.06581 118.3 193
ADP/ATP translocase 1 SLC25A4 Tbio Transporter -2.05462 110.8 89
Charged multivesicular body protein 2b CHMP2B Tbio Non-IDG -1.65708 53.0 166
Nuclear pore complex protein Nup98-Nup96 NUP98 Tbio Enzyme -2.21148 186.3 172
DNA-directed RNA polymerase II subunit RPB7 POLR2G Tbio Enzyme -1.74939 59.4 153
60S ribosomal protein L7a RPL7A Tbio Non-IDG -1.66015 45.9 60
60S ribosomal protein L18 RPL18 Tbio Non-IDG -1.73537 50.7 134